Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Natalizumab Coverage Update | OpenPay…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.059

    Natalizumab and Associated Biosimilar(s)

    Customize your policy alerts

    Sign up for healthspring Policy RX501.059 alerts

    Get alerted when Policy RX501.059 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage for natalizumab (Tysabri) and natalizumab-sztn (Tyruko) for relapsing multiple sclerosis and moderately to severely active Crohn disease in adults. Other non-FDA-approved indications are considered experimental, investigational, and/or unproven, subject to applicable benefit terms and state requirements.

    Policy Summary
    PayerHealthSpring
    PolicyNatalizumab and Associated Biosimilar(s)
    Policy CodePolicy RX501.059
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionEnroll the prescriber and patient in the applicable TOUCH or TYRUKO REMS program and meet all program criteria.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy establishes coverage consideration for natalizumab and natalizumab-sztn for multiple sclerosis and Crohn disease when indication-specific criteria are met.

    2Covered indications
    2Named products
    1MRI before MS therapy
    12 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Crohn benefit assessment
    All otherNon-FDA-approved indications

    Covered and Excluded Uses

    Multiple sclerosis

    Covered as medically necessary when ALL of the following are met.

    • Adult relapsing multiple sclerosis: The patient is 18 years of age or older and has a relapsing form of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.Age ≥18 years
    • Pretreatment imaging: A magnetic resonance imaging brain scan is documented before initiating therapy.MRI brain before initiation

    Crohn disease

    Covered as medically necessary when ALL of the following are met.

    • Disease severity and inflammation: The patient has moderately to severely active Crohn disease with evidence of inflammation.Moderately to severely active disease with evidence of inflammation
    • Prior treatment response or tolerance: The patient has had an inadequate response to, or is unable to tolerate, conventional Crohn disease therapies and TNF-alpha inhibitors.Inadequate response or intolerance to both therapy categories
    • Concomitant therapy restriction: The patient is not also receiving chronic immunosuppressant or immunomodulatory therapy, including 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate, and is not receiving a concomitant TNF-alpha inhibitor.No prohibited chronic concomitant therapy

      Aminosalicylates may continue; steroids should be tapered off by month 6.

    Other indications

    Not covered under this policy.

    Other indications: Use of natalizumab or natalizumab-sztn for any non-FDA-approved indication is considered experimental, investigational, and/or unproven.Non-FDA-approved indication

    Multiple sclerosis program requirements

    Coverage requires compliance with the applicable multiple sclerosis prescribing or REMS program.

    Multiple sclerosis program enrollment: The prescriber and patient must be enrolled in the applicable program and meet all of its criteria.

    For Tysabri, use the MS TOUCH Prescribing Program. For Tyruko, use the MS TYRUKO REMS Program.

    Crohn's disease program requirements

    Coverage requires compliance with the applicable Crohn's disease prescribing or REMS program.

    Crohn's disease program enrollment: The prescriber and patient must be enrolled in the applicable program and meet all of its criteria.

    For Tysabri, use the CD TOUCH Prescribing Program. For Tyruko, use the CD TYRUKO REMS Program.

    For Crohn disease, coverage excludes chronic concomitant immunosuppressant or immunomodulatory therapy, including 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate, as well as concomitant TNF-alpha inhibitor therapy. Aminosalicylates may continue; steroids should be tapered off by month 6. If there is no therapeutic benefit by 12 weeks of induction, discontinuation is recommended. After the initial six-month taper, discontinuation should be considered when additional steroid use exceeds 3 months in a calendar year to control Crohn disease.

    Use of natalizumab or natalizumab-sztn for any non-FDA-approved indication is considered experimental, investigational, and/or unproven and is not covered under this policy.

    Natalizumab products are not indicated for pediatric patients younger than 18 years. Safety and effectiveness in pediatric patients with multiple sclerosis or Crohn disease have not been established.

    Natalizumab and natalizumab-sztn are considered experimental, investigational, and/or unproven for all other non-FDA-approved indications beyond the covered uses for multiple sclerosis and Crohn disease.

    Coding and Clinical Thresholds

    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCS
    J2323Description not provided in document
    Q5134Description not provided in document
    Crohn disease activity
    MeasureCrohn Disease Activity Index (CDAI)
    Minimum activity scoreCDAI of at least 220
    Maximum activity scoreCDAI of no more than 450
    Crohn disease clinical response
    MeasureCrohn Disease Activity Index (CDAI)
    Required responseAt least a 70-point decrease in CDAI from baseline
    Assessment

    Provider Requirements and Decision Points

    Prior Authorization

    MS Safety-Program Enrollment Required

    For Tysabri, the prescriber and patient must be enrolled in and meet all criteria of the MS TOUCH Prescribing Program. For Tyruko, both must meet the requirements of the MS TYRUKO REMS Program.

    • Applies to treatment of relapsing forms of multiple sclerosis.
    • Verify enrollment and eligibility before treatment is initiated.
    Prior Authorization

    Crohn Disease Safety-Program Enrollment Required

    For Tysabri, the prescriber and patient must be enrolled in and meet all criteria of the CD TOUCH Prescribing Program. For Tyruko, both must meet the requirements of the CD TYRUKO REMS Program.

    • Applies to treatment of moderately to severely active Crohn disease.
    • Verify enrollment and eligibility before treatment is initiated.

    Therapy Overview

    Natalizumab (Tysabri) and natalizumab-sztn (Tyruko) are monoclonal antibody therapies used in selected adults with relapsing forms of multiple sclerosis and with moderately to severely active Crohn disease. For multiple sclerosis, treatment is used to reduce the frequency of clinical exacerbations. For Crohn disease, treatment may induce and maintain clinical response and remission in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn disease therapies.

    Clinical and Program Definitions

    Relapsing forms of multiple sclerosis
    Clinically isolated syndromeIncluded as a relapsing form of multiple sclerosis
    Relapsing-remitting diseaseIncluded as a relapsing form of multiple sclerosis
    Active secondary progressive diseaseIncluded as a relapsing form of multiple sclerosis
    Moderately to severely active Crohn disease
    Disease severityModerately to severely active Crohn disease
    Objective findingEvidence of inflammation is required
    Population

    Initial Therapy

    Initial therapy: multiple sclerosis

    Initial therapy for multiple sclerosis may be considered medically necessary when ALL of the following are met.

    Initial multiple sclerosis therapy: The adult patient is at least 18 years of age, has a relapsing form of multiple sclerosis, and has a documented brain MRI before initiating therapy.Age ≥18 years; MRI brain before initiation

    Use is as monotherapy.

    Initial therapy: Crohn disease

    Initial therapy for Crohn disease may be considered medically necessary when ALL of the following are met.

    Initial Crohn disease therapy: The adult patient has moderately to severely active Crohn disease with evidence of inflammation, has had an inadequate response to or cannot tolerate conventional Crohn disease therapies and TNF-alpha inhibitors, and is not receiving prohibited chronic concomitant immunosuppressant, immunomodulatory, or TNF-alpha inhibitor therapy.

    Continuation Therapy

    Crohn disease continuation

    For Crohn disease, natalizumab may be used for inducing and maintaining clinical response and remission, subject to the following ongoing treatment considerations.

    Ongoing Crohn disease therapy: Discontinue therapy if therapeutic benefit has not occurred by 12 weeks of induction; discontinue if chronic concomitant steroids cannot be discontinued within 6 months of starting therapy; after the initial six-month taper, consider discontinuation when additional steroid use exceeds 3 months in a calendar year to control Crohn disease.Benefit by 12 weeks; steroids tapered by 6 months; additional steroid use ≤3 months per calendar year

    These recommendations are attributed to FDA labeling and policy guidance.

    Prior Treatment Requirements

    StepPrior therapy requirementCoverage qualification
    1Prior treatment with conventional Crohn disease therapies and TNF-alpha inhibitorsInadequate response to, or inability to tolerate, both therapy categories is required before natalizumab coverage

    Dose and Administration

    Tysabri and Tyruko
    ProductsTysabri and Tyruko
    RouteIntravenous infusion
    Administration intervalEvery 4 weeks

    Reference Product and Biosimilar

    Billing Rule

    Tysabri and Tyruko are covered treatment options

    For the covered indications, the policy identifies natalizumab (Tysabri) and natalizumab-sztn (Tyruko) as treatment options. No preferential product hierarchy is stated.

    Billing Rule

    Tyruko is a Tysabri biosimilar

    Tyruko is FDA-approved as a biosimilar to Tysabri and was approved for all indications of the reference medicine. The policy does not state a payer-specific preference between the products.

    Billing Rule

    No payer-specific preferred-product rule is stated

    The policy cites FDA prescribing labels for both Tysabri (natalizumab) and Tyruko (natalizumab-sztn). No preferred-product rule is stated, so submit the product prescribed when the applicable coverage criteria are met.

    Policy Summary
    PayerHealthSpring
    PolicyNatalizumab and Associated Biosimilar(s)
    Policy CodePolicy RX501.059
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionEnroll the prescriber and patient in the applicable TOUCH or TYRUKO REMS program and meet all program criteria.
    SourceLink
    On This Page
    Covered and Excluded UsesCoding and Clinical ThresholdsProvider Requirements and Decision PointsTherapy OverviewClinical and Program DefinitionsInitial TherapyContinuation TherapyPrior Treatment RequirementsDose and AdministrationReference Product and Biosimilar
    Clinical response is evaluated as a decrease from the patient's baseline CDAI score
    Crohn disease clinical remission
    MeasureCrohn Disease Activity Index (CDAI)
    Remission thresholdCDAI score below 150
    Clinical outcomeA CDAI below 150 defines clinical remission
    Documentation Required

    Document Relapsing Multiple Sclerosis

    Document that the adult patient has a relapsing form of multiple sclerosis and that treatment is being used as monotherapy. The documented relapsing forms include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • Patient must be 18 years of age or older.
    • Include the MS diagnosis and specific relapsing disease form in the medical record.
    Documentation Required

    Document Crohn Disease Severity and Prior Treatment

    For Crohn disease, document moderately to severely active disease with evidence of inflammation and an inadequate response to, or inability to tolerate, conventional Crohn disease therapies and TNF-alpha inhibitors. Also document that the patient is not receiving chronic immunosuppressant or immunomodulatory therapy, including concomitant TNF-alpha inhibitors.

    • Aminosalicylates may be continued during Tysabri treatment.
    • Steroids should be tapered off by month 6 of Tysabri therapy.
    • Discontinue Tysabri or Tyruko if there is no therapeutic benefit by 12 weeks of induction therapy or chronic steroids cannot be discontinued within 6 months.
    • Beyond the initial six-month taper, consider discontinuation when additional steroid use exceeds 3 months in a calendar year to control Crohn disease.
    Documentation Required

    Complete MS MRI and Follow-Up Surveillance

    Obtain a brain MRI before initiating natalizumab treatment for MS to help differentiate potential MS symptoms from progressive multifocal leukoencephalopathy (PML). Perform follow-up surveillance at 3 and 6 months after the initial infusion, and every 6 months thereafter.

    • Retain the pretreatment MRI and subsequent surveillance documentation in the medical record.
    • Use periodic follow-up to support early identification of potential PML.
    Prior Authorization

    Required Product Risk-Management Program

    Natalizumab products are restricted to enrolled prescribing physicians and patients through required risk-management programs designed to assess and minimize the risk of PML, including death and disability, and to support informed risk-benefit decisions.

    • Tysabri: TOUCH program.
    • Tyruko: TYRUKO REMS Program.
    • Program requirements also include education for prescribers, pharmacists, infusion-center staff, and patients.
    Denial Risk

    Unapproved Indications Not Supported

    Coverage is not supported for natalizumab (Tysabri) or natalizumab-sztn (Tyruko) when used for indications other than the FDA-approved indications for relapsing forms of multiple sclerosis or moderately to severely active Crohn disease meeting policy criteria.

    • Confirm the requested use is an FDA-approved indication before submitting the request.
    Denial Risk

    MS Criteria Not Met

    MS coverage criteria are not met unless the record documents an adult patient with a relapsing form of multiple sclerosis and includes a brain MRI obtained before treatment begins.

    • Relapsing forms include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
    • A diagnosis or disease course outside these relapsing forms does not satisfy the policy.
    • A pretreatment brain MRI is required.
    Denial Risk

    Crohn Disease Criteria Not Met

    Crohn disease criteria are not met unless the record supports moderately to severely active disease with evidence of inflammation, inadequate response to or intolerance of conventional Crohn disease therapies and TNF-alpha inhibitors, and compliance with the restriction against chronic concomitant immunosuppressant or immunomodulatory therapy.

    • Do not approve when the required disease activity, inflammation, or prior-treatment documentation is absent.
    • Do not approve when chronic immunosuppressant, immunomodulatory, or concomitant TNF-alpha therapy is continued.
    • Assess discontinuation if no benefit occurs by 12 weeks, chronic steroids cannot be tapered by 6 months, or later steroid use exceeds 3 months in a calendar year.
    Denial Risk

    Non-FDA-Approved Indication: Denial Risk

    Use of Tysabri or Tyruko for any non-FDA-approved indication is considered experimental, investigational, and/or unproven and presents a denial risk.

    • Limit coverage to approved MS or Crohn disease indications when the applicable policy criteria are met.
    • Classify requests for other uses as experimental, investigational, and/or unproven.
    Definition applies to adult patients considered for treatment
    Progressive multifocal leukoencephalopathy (PML)
    ConditionA rare but potentially fatal brain infection
    CauseReactivation of the John Cunningham virus
    Clinical significanceMay result in severe disability or death
    TYRUKO REMS Program
    ProductTyruko
    Program typeRestricted distribution risk-management program
    PurposeMinimize PML-related death and disability and promote informed risk-benefit decisions
    TOUCH
    ProductTysabri
    Program typeRestricted distribution program
    PurposeAddress the risk of PML and support informed risk-benefit decisions
    Biosimilar
    DefinitionA biologic product highly similar to a reference biologic product
    Biosimilar productTyruko (natalizumab-sztn)
    Reference productTysabri (natalizumab)
    Sustained increase in disability
    Baseline EDSS of at least 1.0An increase of at least 1 point on the EDSS
    Baseline EDSS of 0An increase of at least 1.5 points on the EDSS
    DurationThe increase must be sustained for 12 weeks
    Crohn disease clinical response
    MeasureCrohn Disease Activity Index (CDAI)
    Clinical responseA decrease of at least 70 points from baseline
    ApplicationThe response definition is used to evaluate induction of clinical response
    Crohn disease clinical remission
    MeasureCrohn Disease Activity Index (CDAI)
    Clinical remissionCDAI score below 150
    ApplicationThe remission definition is used to evaluate induction of clinical remission
    Moderately to severely active disease; prior inadequate response or intolerance; no prohibited concomitant therapy

    Aminosalicylates may continue; steroids should be tapered off by month 6.